EU GDP: Good Distribution Practice for Medicinal Products

EU GDP is the European Union framework of minimum good distribution practice standards for maintaining the quality and integrity of medicinal products for human use throughout the wholesale supply chain. This definition follows EMA’s description of GDP, which centres on the standards a wholesale distributor must meet. For the broader distribution concept, see Good Distribution Practice (GDP); this article focuses on the EU framework for human medicines.

The framework has distinct layers. EMA’s legal-framework summary identifies Directive 2001/83/EC as legislation laying down provisions for medicines distribution in the EU. It also states that European Commission guidelines establish GDP requirements. These are different document types: the Directive is legislation, while the Commission documents are guidelines. That distinction does not make the GDP guidelines merely optional advice.

The principal guideline for this article is the Commission’s Guidelines on GDP of medicinal products for human use, identified in EMA’s summary. The search reference 2013/C 343/01 points to that human-medicines guideline. EudraLex Volume 4’s revised GDP guideline entry states that it is applicable as of 24 November 2013 and gives the Official Journal reference OJ C 343/1, 23.11.2013.

Use the following interpretation convention when reading the operational sections:

• Legislation: legal duties are attributed to EMA’s legal summary, without assigning them to individual Directive articles.
• Official guidance: guideline statements retain their guidance attribution rather than being presented as text from the Directive.
• Illustrative practice: proposed controls, checklists and record relationships are operating designs, not additional official requirements.
• Software support: software is discussed as an implementation design, not an independent source of requirements; approval and release decisions remain with authorised people.

For an internal procedure, keep the official requirement separate from the organisation’s chosen method of meeting it. This attribution discipline also helps when connecting distribution procedures to a wider GxP quality framework.

Start with the product, the activity performed and the territory involved. This matrix is a practical scoping aid, not an additional regulatory classification; it organises the source-specific routes explained below.

For the first row, EMA’s wholesale-authorisation statement identifies the EEA wholesale distribution authorisation requirement. The authorisation section explains that route.

For active substances, EMA’s active-substance statement says importers and distributors supplying medicine manufacture in the EEA must register with the relevant national competent authority and comply with GDP principles for active substances. This is the registration route, not the finished-medicine wholesale-authorisation route. Separately, the Commission’s guideline entry identifies the guidelines of 19 March 2015 for active substances for human-use medicines.

Under EMA’s manufacturing-authorisation statement, holders do not need a separate authorisation to distribute products already subject to a manufacturing authorisation. Keep that product boundary intact. EMA’s parallel-distribution statement also expressly requires parallel distributors to comply with GDP.

For veterinary medicinal products, the European Commission lists Regulation (EU) 2021/1248 as the veterinary GDP instrument. Assess that instrument separately rather than importing the human-medicine framework.

This article does not determine the rules for food, supplements, devices, general chemicals or distribution outside the territories discussed. Product classification and the current jurisdiction-specific framework need separate assessment. For a related territorial question, consult the glossary entry on Windsor Framework medicines provisions.

Who authorises and inspects?

Under EMA’s wholesale distribution authorisation summary, anyone engaged in wholesale distribution of medicinal products in the EEA must hold a wholesale distribution authorisation issued by the national competent authority of the Member State where those activities take place. That same national authority is responsible for inspecting the wholesale distributor.

EMA’s authorisation summary also states the legal connection: wholesale distributors must comply with EU GDP to obtain that authorisation. These national functions are distinct from EMA’s coordination role: EMA coordinates the GMP/GDP Inspectors Working Group, comprising senior inspectors appointed by all EEA competent authorities.

Keep the regulatory records distinct

In its EudraGMDP explanation, EMA describes a publicly accessible EU database containing all wholesale distribution authorisations and details of registered importers and distributors of active substances in the EEA. The latter are registration details, not another name for wholesale distribution authorisations.

The same EMA explanation states that, following inspection of a wholesale distributor, EU competent authorities issue a GDP certificate or a non-compliance statement and enter it in EudraGMDP. An authorisation, an inspection-outcome document and the database entry should therefore remain separately identifiable rather than being treated as interchangeable proof.

Certificate extensions and validity questions

EMA’s certificate-validity update states that the pandemic-era general extension ran until the end of 2024 and no longer applies from 2025. This ends the general extension; it does not establish a single invalidation date for every GDP certificate.

Under EMA’s additional-extension and enquiry guidance, national competent authorities decide case by case whether an additional extension is needed. Questions about a certificate and its validity should go to the competent authority that issued it.

A practical record check

For internal review, use separate fields rather than a single “GDP approved” flag. This is an implementation practice, not an official review agenda:

• Authorisation reference: identify the wholesale distribution authorisation being reviewed.
• Inspection-outcome reference: identify the GDP certificate or non-compliance statement separately.
• Database check: record the EudraGMDP lookup date and the entry consulted.
• Unresolved discrepancies: retain conflicting details, the question raised and any authority response as distinct review notes.
• Review ownership: assign a named reviewer and document the relevant local Responsible Person arrangements.

Do not infer validity from document age alone or impose an assumed standard expiry period. Keep an unresolved validity question visible until it has been addressed through the issuing authority.

Behind the authorisation and certificate system sits a layer of shared procedure that distributors rarely read but regularly meet. EMA’s GDP page describes the Agency’s role as “coordinating the preparation of new and revised guidance on GDP” and “developing EU-wide procedures relating to GDP inspections”. Inspection itself stays national: the same national competent authority that issues a wholesale distribution authorisation is responsible for inspecting the distributor. EMA’s contribution is to make those national inspections comparable.

The GMP/GDP Inspectors Working Group

EMA coordinates a working group of senior inspectors appointed by all EEA competent authorities. The page says it “meets at EMA four times a year” and provides “a forum for harmonisation and discussion of common issues”, such as updates to the EU GDP guidelines and the compilation of Union procedures. Its questions and answers are the interpretive layer a distributor’s quality assurance team should check when the guideline text leaves a practical question open, recorded as interpretation rather than as a new legal duty.

The Compilation of Union procedures

EMA maintains a compilation of GDP and GMP inspection-related procedures and forms agreed by all Member States. According to the page, it covers “how quality defects and non-compliance are handled and how GMP and GDP inspections are carried out and reported”. For a distributor this has two practical consequences. First, the agreed procedures support harmonisation of inspections; applicability to each site and local requirements still need to be checked. Second, the compilation is where the shared vocabulary for quality defects and non-compliance comes from, which helps when a distributor has to describe a problem to more than one authority.

Rapid alerts and recalls

EMA has published Word versions of two templates from the compilation “for the convenience of inspectorates”: a Rapid alert notification of a quality defect / recall, and a Follow-up and non-urgent information for quality defects form. EMA states that these versions are published for the convenience of inspectorates. Their structure is still a useful test of a distributor’s own recall and complaint records: if an authority were to issue a rapid alert about a batch the distributor handled, could the distributor say within its own procedure which customers received that batch, when, and under which storage conditions? That proposed record test adds practical detail to EMA’s broader recommendation that the distributor “should also put in place a tracing system to enable finding faulty products and an effective recall procedure”.

Parallel distribution follows the same logic. EMA states that “Parallel distributors also must comply with GDP”, so a parallel distributor’s storage, transport and tracing evidence is held to the same guidelines as any other wholesale distributor’s, even though the commercial route differs.

EMA’s statement that compliance with GDP ensures these results identifies five distribution outcomes. This regulator summary is not a complete chapter-by-chapter legal checklist:

1. Medicines in the supply chain are authorised in accordance with EU legislation.
2. Medicines are stored in the right conditions at all times, including during transportation.
3. Contamination by or of other products is avoided.
4. Adequate turnover of stored medicines takes place.
5. The right products reach the right addressee within a satisfactory time period.

Turning outcomes into local controls

The following matrix is an illustrative implementation tool, not an EMA-prescribed management-review agenda. Owners are suggested local roles; the table does not establish a required review frequency or sign-off roster.

For local design detail, connect the relevant rows to temperature monitoring, spillage and cross-contamination control, and FEFO picking controls. Adapt each row to the products and routes involved. Where evidence is missing, record the unresolved question and assign a person to investigate rather than treating a completed table as proof that the outcome was achieved.

To support the condition outcome above, a practical evidence chain could connect each storage location or shipment to its affected batch, monitoring device and observation times. These are proposed record relationships, not additional guideline provisions. A cold-chain data logger record is more useful for investigation when those connections are explicit.

Worked case: duration is not disposition

Assume a hypothetical shipment has a site-defined investigation band of 2–8 °C. This band is an example assumption, not a universal EU GDP limit. Continuous monitoring and synchronised timestamps show an uninterrupted 9 °C interval from 10:14 to 10:36 on the same day.

The recorded interval is exactly 22 minutes: 10:36 minus 10:14. That calculation describes the observation; it does not determine whether the product remains suitable. Assemble the affected batch identity, observation record, relevant product information and handling history for an authorised person’s assessment. Neither release, rejection nor destruction follows from these numbers alone.

Limits of interpretation

Without a location or shipment link, the observation may not identify which stock was affected. Without device identity, it may be difficult to connect the reading to the instrument’s history. Without a reliable time reference, duration and sequence may be uncertain; clock drift monitoring is relevant to that uncertainty. Leave detailed monitoring specifications and acceptance criteria to the applicable product and operating context rather than treating this example as a monitoring specification or acceptance rule.

EMA’s GDP overview gives this guidance: “The distributor should also put in place a tracing system to enable finding faulty products and an effective recall procedure.”

An illustrative operating sequence connects receipt records to delivery evidence and recall tracing. It is a proposed implementation approach, not an official inspection checklist:

1. Establish the product and activity scope, then identify suppliers, receiving sites and consignees in party records.
2. Receive and identify stock, recording the product, batch and quantity against the receipt.
3. Associate each batch quantity with its storage location; preserve those relationships when stock moves.
4. Assemble dispatch records linking batch quantities to the intended consignee.
5. Record transport handover against the dispatch, so the consignment remains identifiable beyond the warehouse.
6. Reconcile delivery information with dispatched quantities and investigate differences.
7. Use the same batch, location and consignee relationships to trace affected stock.

Bin-level lot genealogy supports the location question; recall readiness concerns whether those relationships can be used promptly.

Worked case: accounted for is not recovered

Assume one batch receipt of 1,200 packs, with no losses or adjustments. Before recall returns, 450 packs remain in storage, 500 went to consignee A and 250 went to consignee B. The reconciliation is 450 + 500 + 250 = 1,200 packs: 100% of the received quantity is accounted for.

Dispatched quantity is 500 + 250 = 750 packs. If 300 dispatched packs are returned during the recall exercise, physical recovery is 300 ÷ 750 × 100 = 40%, leaving 450 dispatched packs outstanding. Complete quantity reconciliation is not completed physical recovery. In warehouse recall execution, track return status separately from the authorised person’s closure decision; this calculation supplies no legal closure threshold.

A useful distribution evidence model connects records rather than merely displaying statuses. The five-entity diagram below is an illustrative information-design proposal, not an EMA-mandated database schema. Its fields provide starting points for organising evidence; they are not a complete implementation specification.

Here, party_id connects a shipment to its consignee; batch_id connects stock and movement records; shipment_id connects condition observations to movement; and related_record_id connects an exception decision to the record assessed. A real implementation must define the referenced record type, represented here by related_record_type, and each identifier’s scope—for example, whether identifiers are unique across sites. For multi-batch shipments, the design should support a batch_id for each shipment line rather than one batch per shipment.

Preserve evidence behind the status

A summary such as “checked” or “acceptable” is not the underlying record. Consider retaining the source, reference, checker and time of an authorisation check; the origin, observation time and units of a condition measurement; and the identity, time, rationale and evidence references of a human decision. For a cold-chain data logger, distinguish measurement time from import time. These are proposed provenance controls, not universal retention periods, electronic-signature rules or validation obligations.

Software can serve as a place to organise these records and route proposed workflows; it is not the source of an authorisation, certificate or product disposition. In this design, authorised people approve decisions and releases.

Navigate one exception

Starting with an exception_id for a shipment-related deviation, identify the related shipment, follow batch_id to stock and movements, then retrieve the associated condition observations and human decision. This navigation lets a reviewer examine the evidence supporting the conclusion without treating a summary status as proof.

Use the following comparison as a navigation aid, not as a statement that neighbouring frameworks are interchangeable. It separates the EU-specific discussion from broader terminology, manufacturing guidance and local implementation.

Manufacturing and distribution guidance sit side by side in the Commission’s EudraLex Volume 4, but they are not the same instrument. For distribution, EMA’s GDP page names the two Commission guidelines that “establish the requirements of GDP”: the Guidelines on GDP of medicinal products for human use, and the Guidelines on principles of GDP for active substances for medicinal products for human use. Start there for a distribution question, and turn to GMP material only where the activity is manufacturing.

EMA’s interpretation statement identifies the GMP/GDP Inspectors Working Group’s Q&As as additional interpretation of the EU GMP and GDP guidelines. Read them in that interpretive role, not as replacements for legislation or the guidelines.

A practical source-selection sequence

1. Identify the activity and product using the scope matrix above before selecting a document.
2. Label each statement by origin: binding legislation, official guidance or a local procedure. Keep suggested implementation choices distinguishable.
3. Retain the source title and scope when transferring a statement into a checklist, training document or procedure.
4. For national procedures or non-EEA operations, check the current applicable framework rather than assuming equivalence.

Use this suggested internal preparation sequence to organise a focused walkthrough. It is not an EMA-prescribed inspection dossier or management-review checklist. Apply the framework and regulatory-record distinctions covered above; assembling a file does not itself prove compliance.

1. Record the product, activity and territory assessment, including any scope questions that remain unresolved.
2. Assemble the relevant authorisation or registration references identified in the earlier applicability and authorisation sections.
3. Retain the regulatory-record check: what was checked, when, the result and any questions requiring follow-up.
4. Walk one batch through receipt, storage and dispatch evidence, following the proposed record relationships rather than reviewing documents in isolation.
5. Retrieve its condition observations and connect the relevant temperature-monitoring records to the movement under review.
6. Test the tracing calculation used for recall readiness, keeping quantities located separate from quantities actually recovered.
7. Demonstrate an exception record and an interface-recovery record, including the reconciliation that explains the final quantities and record status.
8. Identify outstanding decisions, their authorised owners and the evidence each owner needs before deciding.

Keep the exercise narrow: choose one representative movement, follow its evidence links and note where identifiers, observations or decisions cannot be connected. Assign corrective work for each broken link, with an owner and a follow-up point. Use the competent-authority route discussed above for unresolved certificate questions. Finish with a clear list of demonstrated connections, remaining gaps and pending human decisions—not a blanket declaration of readiness.